A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. John Leonard, Director of the Weill Cornell Lymphoma Program, was on the panel of experts participating in Cancer Care’s Connect Education Workshop titled, “Understanding the Importance of Clinical Trials: What You Need to Know” in May 2011.
Click the player below to listen to the Connect Education Workshop, or click here to download the discussion on the Cancer Care website.
BioTime, Inc. announced today it has entered into an exclusive agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells. Potential uses of this technology may include a new modality for targeting cancer tumors.
Vascular endothelial cells form the blood vessels that support the growth of cancerous tumors. The technology may be used to derive vascular endothelial cells engineered to “deliver a toxic payload to the developing blood vessels of a tumor to remove malignant tumors while not affecting nearby normal tissues.”
Click here to read the full article.
Weill Cornell’s Dr. Melnick also discusses why turning science into medicine is happening much more rapidly.
New Developments in Lymphoma 